At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 112 enrolled
Drug / intervention
Exparel 133 MG Per 10 ML Injection +1 moredrug
Likely dose
Exparel 133 MG Per 10 ML Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prolonging the Interscalene Brachial Plexus Block by Adding Liposomal Bupivacaine or Preservative Free Dexamethasone to Bupivacaine: a Non-inferiority Trial
In Brief
A Phase 4 clinical trial evaluating Exparel 133 MG Per 10 ML Injection and Dexamethasone for Shoulder Pain. Completed, enrolled 112 participants across 1 site.
Detailed Summary
In this study, patients receiving shoulder arthroscopy will receive an interscalene block for pain management containing either liposomal bupivacaine and standard bupivacaine or standard bupivacaine and dexamethasone. Patients will be followed up with to determine postoperative pain and block duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShoulder Pain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
First PostedAug 2019
Primary CompletionMar 2021
Study CompletionMar 2021
TodayJul 2026
First PostedAug 6, 2019
Enrollment StartJul 11, 2019
Primary CompletionMar 15, 2021
Study CompletionMar 19, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.9 years ago
Interventions
Exparel 133 MG Per 10 ML Injectiondrug
10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
Dexamethasonedrug
15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected